AVAH
BEARISH
$6.91
Live
Aveanna Healthcare Holdings Inc. · NASDAQ
Target $11.0
(+59.2%)
$3.73
52W Range
$10.32
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 19, 2026
Market cap
$1.44B
P/E
18.68
ROE
N/A
Profit margin
3.3%
Debt/Equity
152.32
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AVAH's Piotroski F-Score of 5/9 indicates a borderline stable financial health, but the absence of an Altman Z-Score and a dangerously high Debt/Equity ratio of 152.32 signal severe financial distress risk. Despite strong revenue growth (22.2% YoY) and impressive earnings surprises (average +362.87% in last 4 quarters), the company trades at a premium valuation (P/E 18.68, Price/Book 147.02) with no dividend and negative ROE. Insider selling totaling $7.14M in 6 months further undermines confidence, while the stock has underperformed over the past 6 months despite a 3-year gain of 506.1%. The Graham Number of $0.63 suggests deep undervaluation, but the intrinsic value of $2.59 is not supported by current fundamentals, indicating the market prices in aggressive growth expectations.
Key Strengths
Strong revenue growth of 22.2% YoY
Exceptional earnings surprise history (avg +362.87% in last 4 quarters)
High gross margin of 33.57% indicates pricing power and operational efficiency
Positive operating margin of 11.00% despite high leverage
Analyst consensus of 'buy' with a $11.00 target price (52% upside)
Key Risks
Piotroski F-Score of 5/9 indicates weak financial health; below threshold for strong stability
Debt/Equity ratio of 152.32 is extremely high and unsustainable
No Altman Z-Score available; risk of distress is elevated due to leverage
Insider selling of $7.14M in 6 months signals negative sentiment from leadership
Price/Book of 147.02 is absurdly high, indicating extreme overvaluation relative to book value
AI Fair Value Estimate
Based on comprehensive analysis
$2.59
-62.5% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
39
Weak
30
75
65
25
0
AI Verdict
Weak
Key drivers: High revenue growth and earnings surprises, Extremely high leverage and poor financial health, Negative insider sentiment, Overvalued on multiple metrics, Lack of profitability metrics (ROE, ROIC)
Confidence
85%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Graham Number of $0.63 suggests deep undervaluation
- Intrinsic value estimate of $2.59 provides a theoretical floor
Watchpoints
- Current price of $6.91 is 174% above intrinsic value
- Price/Book of 147.02 is unsustainable
- P/E of 18.68 is high relative to peers and fundamentals
Future
75/100
Ref Growth rates
Positives
- 22.2% YoY revenue growth indicates strong top-line momentum
- Recent earnings surprises suggest potential for continued upside
Watchpoints
- No forward P/E or PEG available, limiting growth assessment
- Q/Q EPS growth of -16.7% suggests near-term deceleration
Past
65/100
Ref Historical trends
Positives
- 3 out of last 4 quarters beat estimates
- Average earnings surprise of +362.87% in last 4 quarters
Watchpoints
- Historical earnings volatility with multiple negative surprises
- 2022-2023 saw multiple quarters with negative EPS and large misses
Health
25/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Operating margin of 11.00% is positive
- Current ratio of 1.23 and quick ratio of 1.15 indicate minimal liquidity risk
Watchpoints
- Piotroski F-Score of 5/9 is below stable threshold
- Debt/Equity of 152.32 is catastrophic
- No Altman Z-Score available; distress risk is high
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$6.91
Analyst Target
$11.0
Upside/Downside
+59.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AVAH and closest competitors.
Updated 2026-03-18
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AVAH
Aveanna Healthcare Holdings Inc.
Primary
|
-42.4% | +506.1% | +26.3% | -14.5% | -9.6% | -1.7% |
|
GLUE
Monte Rosa Therapeutics, Inc.
Peer
|
-14.8% | +121.2% | +344.6% | +113.4% | +4.5% | +5.6% |
|
AHCO
AdaptHealth Corp.
Peer
|
-72.3% | -20.2% | +10.2% | +14.1% | +0.5% | +11.6% |
|
TNDM
Tandem Diabetes Care, Inc.
Peer
|
-77.5% | -43.3% | +29.6% | +36.7% | -14.4% | +5.7% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
AVA
Aveanna Healthcare Holdings Inc.
Primary
5Y
-42.4%
3Y
+506.1%
1Y
+26.3%
6M
-14.5%
1M
-9.6%
1W
-1.7%
GLU
Monte Rosa Therapeutics, Inc.
Peer
5Y
-14.8%
3Y
+121.2%
1Y
+344.6%
6M
+113.4%
1M
+4.5%
1W
+5.6%
AHC
AdaptHealth Corp.
Peer
5Y
-72.3%
3Y
-20.2%
1Y
+10.2%
6M
+14.1%
1M
+0.5%
1W
+11.6%
TND
Tandem Diabetes Care, Inc.
Peer
5Y
-77.5%
3Y
-43.3%
1Y
+29.6%
6M
+36.7%
1M
-14.4%
1W
+5.7%
BCR
BioCryst Pharmaceuticals, Inc.
Peer
5Y
-25.9%
3Y
-38.3%
1Y
-12.2%
6M
-20.6%
1M
-11.8%
1W
+1.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
18.68
Forward P/E
11.27
PEG Ratio
N/A
P/B Ratio
147.02
P/S Ratio
0.63
EV/Revenue
1.22
EV/EBITDA
10.51
Market Cap
$1.44B
Profitability
Profit margins and return metrics
Profit Margin
3.29%
Operating Margin
11.0%
Gross Margin
33.57%
ROE
N/A
ROA
9.31%
Growth
Revenue and earnings growth rates
Revenue Growth
+22.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
152.32
High debt
Current Ratio
1.23
Good
Quick Ratio
1.15
Good
Cash/Share
$0.73
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.6B
Gross Margin
32.6%
Op. Margin
8.4%
Net Margin
2.3%
Total Assets
$1.8B
Liabilities
$1.8B
Equity
$0.0B
Debt/Equity
181.62x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
94%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-19
$N/A
2025-11-06
$0.15
+14.9% surprise
2025-08-07
$0.18
+405.5% surprise
2025-05-08
$0.03
+668.2% surprise
Healthcare Sector Comparison
Comparing AVAH against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
18.68
This Stock
vs
75.44
Sector Avg
-75.2%
(Discount)
Profit Margin
3.29%
This Stock
vs
-16.28%
Sector Avg
-120.2%
(Weaker)
Debt to Equity
152.32
This Stock
vs
2.66
Sector Avg
+5621.7%
(Higher)
Revenue Growth
22.2%
This Stock
vs
124.04%
Sector Avg
-82.1%
(Slower)
Current Ratio
1.23
This Stock
vs
4.47
Sector Avg
-72.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AVAH
Aveanna Healthcare Holdings Inc.
|
BEARISH | $1.44B | 18.68 | -% | 3.3% | $6.91 | |
|
GLUE
Monte Rosa Therapeutics, Inc.
|
NEUTRAL | $1.44B | - | -16.9% | -31.2% | $18.05 | Compare |
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | - | -4.3% | -2.2% | $10.6 | Compare |
|
TNDM
Tandem Diabetes Care, Inc.
|
BEARISH | $1.46B | - | -97.9% | -20.2% | $21.24 | Compare |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 | Compare |
AVAH
Aveanna...
BEARISH
Mkt Cap
$1.4B
P/E
18.7
ROE
-%
Price
$6.91
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-19 | SHANER JEFFREY | Chief Executive Officer | Sale | 461,909 | $3,411,399 |
| 2026-02-19 | REISZ EDWIN C | Officer | Sale | 162,043 | $1,196,758 |
| 2026-02-19 | CUNNINGHAM PATRICK A | Officer | Sale | 49,160 | $363,068 |
| 2026-02-19 | STEWART DEBORAH | Officer | Sale | 29,815 | $220,197 |
| 2026-02-19 | BUCKHALTER MATTHEW | Chief Financial Officer | Sale | 36,030 | $266,097 |
| 2026-02-13 | GANZI VICTOR F. | Director | Stock Award | 18,916 | - |
| 2026-02-13 | WINDLEY RODNEY D | Director | Stock Award | 289,947 | - |
| 2026-02-13 | RODGERS STEVEN E | Director | Stock Award | 18,916 | - |
| 2026-02-13 | SHANER JEFFREY | Chief Executive Officer | Stock Award | 715,229 | - |
| 2026-02-13 | LAYTON BRENT D | Director | Stock Award | 18,916 | - |
| 2026-02-13 | REISZ EDWIN C | Officer | Stock Award | 287,457 | - |
| 2026-02-13 | CUNNINGHAM PATRICK A | Officer | Stock Award | 91,797 | - |
| 2026-02-13 | SCHWARTZ ERICA | Director | Stock Award | 18,916 | - |
| 2026-02-13 | STEWART DEBORAH | Officer | Stock Award | 79,099 | - |
| 2026-02-13 | BUCKHALTER MATTHEW | Chief Financial Officer | Stock Award | 128,293 | - |
SHANER JEFFREY
Chief Executive Officer
2026-02-19
461,909 shares
·
$3,411,399
REISZ EDWIN C
Officer
2026-02-19
162,043 shares
·
$1,196,758
CUNNINGHAM PATRICK A
Officer
2026-02-19
49,160 shares
·
$363,068
STEWART DEBORAH
Officer
2026-02-19
29,815 shares
·
$220,197
BUCKHALTER MATTHEW
Chief Financial Officer
2026-02-19
36,030 shares
·
$266,097
GANZI VICTOR F.
Director
2026-02-13
18,916 shares
WINDLEY RODNEY D
Director
2026-02-13
289,947 shares
RODGERS STEVEN E
Director
2026-02-13
18,916 shares
SHANER JEFFREY
Chief Executive Officer
2026-02-13
715,229 shares
LAYTON BRENT D
Director
2026-02-13
18,916 shares
REISZ EDWIN C
Officer
2026-02-13
287,457 shares
CUNNINGHAM PATRICK A
Officer
2026-02-13
91,797 shares
SCHWARTZ ERICA
Director
2026-02-13
18,916 shares
STEWART DEBORAH
Officer
2026-02-13
79,099 shares
BUCKHALTER MATTHEW
Chief Financial Officer
2026-02-13
128,293 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
10 analysts
Barclays
2026-01-16
Overweight
Overweight
UBS
2026-01-15
Neutral
Neutral
RBC Capital
2026-01-15
Sector Perform
Sector Perform
William Blair
2025-12-08
Outperform
BMO Capital
2025-11-13
Outperform
UBS
2025-11-07
Neutral
Neutral
Truist Securities
2025-11-07
Hold
Hold
Jefferies
2025-10-28
Buy
Buy
RBC Capital
2025-10-24
Sector Perform
Sector Perform
UBS
2025-10-13
Neutral
Neutral
Past News Coverage
Recent headlines mentioning AVAH from our newsroom.
Newest → oldest
No matching news yet.